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BACKGROUND & AIMS: More than 20% of patients with in-
flammatory bowel disease (IBD) discontinue thiopurine ther-
apy because of severe adverse drug reactions (ADRs);
leukopenia is one of the most serious ADRs. Variants in the
gene encoding thiopurine S-methyltransferase (TPMT) alter its
enzymatic activity, resulting in higher levels of thiopurine me-
tabolites, which can cause leukopenia. We performed a pro-
spective study to determine whether genotype analysis of
TPMT before thiopurine treatment, and dose selection based on
the results, affects the outcomes of patients with IBD.
METHODS: In a study performed at 30 Dutch hospitals, patients
were assigned randomly to groups that received standard
treatment (control) or pretreatment screening (intervention) for
3 common variants of TPMT (TPMT*2, TPMT*3A, and TPMT*3C).
Patients in the intervention group found to be heterozygous
carriers of a variant received 50% of the standard dose of thi-
opurine (azathioprine or 6-mercaptopurine), and patients ho-
mozygous for a variant received 0%–10% of the standard dose.
We compared, in an intention-to-treat analysis, outcomes of the
intervention (n ¼ 405) and control groups (n ¼ 378) after 20
weeks of treatment. Primary outcomes were the occurrence of
hematologic ADRs (leukocyte count < 3.0*109/L or reduced
platelet count < 100*109/L) and disease activity (based on the
Harvey–Bradshaw Index for Crohn’s disease [n ¼ 356] or the
partial Mayo score for ulcerative colitis [n ¼ 253]). RESULTS:
Similar proportions of patients in the intervention and control
groups developed a hematologic ADR (7.4% vs 7.9%; relative
risk, 0.93; 95% confidence interval, 0.57–1.52) in the 20 weeks
of follow-up evaluation; the groups also had similar mean levels
of disease activity (P ¼ .18 for Crohn’s disease and P ¼ .14 for
ulcerative colitis). However, a significantly smaller proportion of
carriers of the TPMT variants in the intervention group (2.6%)developed hematologic ADRs compared with patients in the
control group (22.9%) (relative risk, 0.11; 95% confidence in-
terval, 0.01–0.85). CONCLUSIONS: Screening for variants in
TPMT did not reduce the proportions of patients with hemato-
logic ADRs during thiopurine treatment for IBD. However, there
was a 10-fold reduction in hematologic ADRs among variant
carriers who were identified and received a dose reduction,
compared with variant carriers who did not, without differences
in treatment efficacy. ClinicalTrials.gov number: NCT00521950.
Keywords: Leukocyte; Adverse Event; Pharmacogenetic; Side
Effect.
hiopurines are effective to induce and maintain long-Tterm remission in up to 70% of patients with in-
flammatory bowel disease (IBD) (Crohn’s disease [CD] and
ulcerative colitis [UC]).1 Azathioprine and 6-mercaptopurine
are inactive prodrugs that need to undergo intracellular
conversion to pharmacologically active 6-thioguanine
nucleotides before exerting their cytotoxic action on (over-
active) immune cells. Thiopurine S-methyltransferase (TPMT)
metabolizes thiopurines to inactive metabolites, leaving less
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ATparent drug to be metabolized to active 6-thioguanine
nucleotides.2,3 Approximately 10% of Caucasians carry a ge-
netic variant in the TPMT gene, resulting in decreased TPMT
enzyme activity and consequently higher 6-thioguanine
nucleotide levels and a higher risk of potentially life-
threatening myelosuppression during thiopurine treatment.4
More than 20% of IBD patients discontinue thiopurine
treatment owing to (serious) adverse drug events.5,6 Cur-
rent guidelines for thiopurine treatment mandate regular
hematologic monitoring to detect (severe) myelotoxicity,
most commonly presenting as leukopenia and to a lesser
extent as thrombocytopenia.1 However, this is not a com-
plete safeguard because myelotoxicity can develop suddenly
at any time point during treatment, and patients with bone
marrow suppression have a higher cumulative incidence of
infections, mortality, and death.1,7 This underscores the
importance of treating patients as safely as possible (ie,
based on genotype) from treatment start. Pharmacogenetic
testing for TPMT has been advocated for a long time to
optimize the safety of thiopurine treatment, but clinical use
of pretreatment TPMT testing has been low, and effective-
ness data are lacking.8 To date, 2 TPMT-related, random-
ized, controlled trials have been performed, one including
patients with a range of inflammatory conditions, but
mainly IBD (85% of the patients included), the other study
including 29 IBD patients. Definitive conclusions could not
be drawn from either study.9,10 A recent meta-analysis (n ¼
4306 patients) suggested that IBD patients with decreased
TPMT activity are indeed at increased risk of developing
leukopenia compared with patients with normal TPMT
activity.3
In general, pharmacogenetic testing to optimize treat-
ment is applied only on a limited scale in clinical practice to
date because large-scale, randomized, controlled trials
proving the effectiveness of available tests largely are
lacking.11–13 This also is hampering for the clinical uptake of
TPMT testing before thiopurine treatment. In this random-
ized controlled trial (Thiopurine response Optimization by
Pharmacogenetic testing in Inflammatory bowel disease
Clinics [TOPIC]), we investigated whether pretreatment
TPMT genotyping followed by personalized dosing results in
a reduced incidence of hematologic adverse drug reactions
(ADRs). In addition, we evaluated the influence of this safety
optimizing strategy on clinical outcome and other ADRs.Materials and Methods
Patients
Patients were assessed for eligibility by their gastroenter-
ologist. Patients who met the inclusion criteria were assigned
randomly to pretreatment TPMT genotyping (intervention
group) or standard treatment (control group). Inclusion criteria
were as follows: age older than 18 years and a diagnosis of IBD.
Exclusion criteria were as follows: previous use of azathioprine
or 6-mercaptopurine, co-treatment with allopurinol, leukocyte
count less than 3.0*109/L, liver test abnormalities (liver
enzyme levels [alanine aminotransferase, aspartate amino-
transferase, alkaline phosphatase, and/or g-glutamate trans-
peptidase] 2 times normal upper limit), reduced renalfunction (creatinine serum level 2 times normal upper limit),
known TPMT enzyme activity or genotype, and current
pregnancy.
The study protocol was approved by the Institutional Re-
view Board of the Radboud university medical center (Com-
missie Mensgebonden Onderzoek Regio Arnhem Nijmegen,
protocol number: 13171), approval for inclusion of patients in
other institutes was obtained from institutional ethics com-
mittee. All patients provided written informed consent. This
study is registered at clinicaltrials.gov (NCT00521950).
Study Design
Thirty Dutch hospitals participated in the parallel ran-
domized controlled trial. Patients were enrolled by the TOPIC
recruitment team (see Acknowledgment section for a list of
TOPIC collaborators). Randomization was based on a
computer-generated schedule per participating center with a
block size of 4 (developed by C.J.v.M.). Gastroenterologists and
patients were blinded to randomization. All authors had access
to the study data and have reviewed and approved the final
manuscript.
Blood samples for TPMT genotyping and enzyme mea-
surements were collected from every patient before treatment
initiation, and were numbered upon arrival at the laboratory.
Only patients assigned to the intervention group underwent
pretreatment testing for 3 common TPMT variants (TPMT*2
[238G>C (rs1800462)], TPMT*3A [460G>A (rs1800460) and
719A>G (rs1142345)], and TPMT*3C [rs1142345]), account-
ing for approximately 95% of the variant alleles observed in
Caucasians.5,14,15 The turn-around time for genotyping results
(intervention group) and dosing advice (all patients) was 5
working days. Patients in the control group and patients who
did not carry a TPMT variant were treated according to stan-
dard IBD guidelines (2–2.5 mg/kg/day azathioprine or 1–1.5
mg/kg/day 6-mercaptopurine). Patients in the intervention
group who carried a genetic variant received 50% (heterozy-
gotes) or 0%–10% (homozygotes) of the standard thiopurine
dose according to the evidence-based guidelines of the Dutch
Pharmacogenetics Working Group.16 For all patients (inter-
vention and control groups) a letter containing the dose advice
was sent to the gastroenterologist. The majority of the patients
(n ¼ 705; 90%) received advice for the standard dose ac-
cording to the Dutch guidelines. The study was not blinded.
Gastroenterologists were allowed to change the thiopurine
dose or stop treatment when a side effect occurred. The
following guidelines were provided: consider a dose reduction
by a count of 4*109/L or less and a fast decrease of leukocyte
count, dose reduction of 50% by a leukocyte count of 3*109/L
or less, and treatment stop by a leukocyte count of less than
1*109/L. Treatment re-challenge was at the discretion of the
gastroenterologist.
The primary outcome of the study was the development of a
hematological ADR. Secondary outcomes based on blood levels
were signs of hepatotoxicity, pancreatitis, or anemia. Secondary
outcomes reported by clinicians included general side effects
(dizziness, shivers, fever, general malaise), gastrointestinal side
effects (stomach ache, diarrhea, reduced appetite, nausea, and
vomiting), hepatic side effects (cholestasis, cholangitis, hepati-
tis, and steatosis), dermatological side-effects (hair loss, warts,
and skin rash), myalgia, and arthralgia. Included patients were
followed up for 20 weeks after thiopurine treatment initiation.





ATBlood for biochemical measurements was collected at least 1
week before study start and at weeks 1, 2, 4, 6, 8, and 20.
Erythrocyte sedimentation rate (ESR) and C-reactive
protein (CRP) levels were measured before treatment start and
at 20 ± 6 weeks. Leukocytes, thrombocytes, hemoglobin, he-
matocrit, mean corpuscular volume, liver enzymes (alanine
aminotransferase, aspartate aminotransferase, alkaline phos-
phatase, and g-glutamate transpeptidase), and amylase or
lipase were measured at every visit. At week 8, blood
samples were collected for 6-thioguanine nucleotide and 6-
methylmercaptopurine ribonucleotide metabolite measure-
ment; metabolites were assessed after follow-up evaluation.
Clinical evaluation was performed before study start and at
week 20 ± 6 weeks to determine disease location and activity.
During the follow-up period, clinical information (complica-
tions and changes in treatment such as changes of azathio-
prine/6-mercaptopurine dose or co-medication) was collected
when patients had contact with the gastroenterologist, timing
and intervals of which were at the discretion of the clinician.
Patients received questionnaires concerning disease activity
(number of [liquid] stools, abdominal pain, fever, use of anti-
diarrheal medication, general well-being) 1 week before treat-
ment initiation and at week 20. These data, in combination with
clinical measures, were used to calculate the disease activity
(Harvey–Bradshaw Index [HBI] for CD and partial Mayo for
UC). For the HBI, we used abdominal mass measured before
treatment initiation in case this measure was missing at 20
weeks.
Genotyping
Genetic analysis was performed in a ISO15189-accredited
laboratory (Human Genetics Department, Radboud university
medical center, Nijmegen, The Netherlands). Genotyping of 3
common TPMT variants (TPMT*2, TPMT*3A, and TPMT*3C,
UCSC Genome Browser [genome.ucsc.edu] accession number:
NM_000367.3) was performed using TaqMan SNP genotyping
assays according to the manufacturer protocol (Life Technolo-
gies, Bleiswijk, The Netherlands: rs1800462: assay-
ID:C__12091552_30; rs1800460: assay-ID:C__30634116_20;
and rs1142345: assay-ID:C_____19567_20). Signals were detec-
ted with the 7500 Fast Real-Time Polymerase Chain Reaction
System (Life Technologies) and subsequently analyzed using
Allelic Discrimination software version 1.4 (Life Technologies).
All patients in the intervention arm were genotyped in tripli-
cate. Patients assigned to the control group were genotyped in
one batch in duplicate after the follow-up period of 20 weeks.
Each genotyping experiment contained at least 4 positive con-
trols for each TPMT variant. Five percent of samples were
genotyped in duplicate (within or between plates); all geno-
types were concordant. Sequencing of the protein coding part
of the TPMT gene was performed in a subset of patients
(Supplementary Table 1).
Enzyme and Metabolite Measurements
TPMT enzyme activity and thiopurine metabolites were
assessed after the follow-up period had ended. Blood for TPMT
enzyme activity measurements was collected before treatment
initiation and stored at -80C until further processing. Enzyme
activity was measured in red blood cells (RBCs) using a
high-performance liquid chromatography method described
previously.17Blood samples for 6-thioguanine nucleotide and 6-
methylmercaptopurine ribonucleotide measurement were
stored immediately at 2C–8C and sent to the Department of
Clinical Pharmacy and Toxicology (Orbis Medical Centre,
Sittard-Geleen, The Netherlands), where samples were pro-
cessed and stored at -20C until required. 6-Thioguanine nu-
cleotides and 6-methylmercaptopurine ribonucleotides levels
were determined with a modified high-performance liquid
chromatography method as published previously.18 Lower
limits of quantification for 6-thioguanine nucleotide and
6-methylmercaptopurine ribonucleotide metabolite levels
were 40 pmol/8  108 RBCs and 300 pmol/8  108 RBCs,
respectively. Interassay variability for both 6-thioguanine nu-
cleotides and 6-methylmercaptopurine ribonucleotides was
less than 10%.Statistical Analysis
The study was designed to have 80% power with inclusion
of 388 patients per treatment arm and a reduction in hema-
tologic ADR rate of 50% (hematologic ADR rate of 11% in the
nongenotyped group and 5.5% in the genotyped group; 2-sided
P value threshold was .05).5
The data set was analyzed on an intention-to-treat basis
after exclusion of patients who were lost to follow-up evalua-
tion (Supplementary Figure 1). Differences in baseline variables
and ADRs between patients grouped as intervention or control
were assessed using the Pearson X2 test, the Fisher exact test,
the Student t test, the Mann–Whitney U test, or an independent
sample Kruskal–Wallis test, as appropriate. Hardy–Weinberg
equilibrium was assessed using a X2 test. Primary outcomes of
the study were as follows: (1) occurrence of hematologic ADRs
defined as a leukocyte count of 3.0*109/L or less (which is
indicative of an increased risk for serious systemic infections)
within the follow-up period of 20 ± 6 weeks, or platelet count
less than 100*109/L; and (2) clinical outcome based on disease
activity scores. Secondary outcomes were the occurrence of
other (severe) ADRs. Post hoc comparisons for patients with
and without a variant between the intervention and control
groups were performed for the primary outcome hematologic
ADRs using the Pearson X2 test. Analyses were performed using
IBM SPSS Statistics for Windows, Version 20.0 (release 20.0.0.1;
IBM Corp, Armonk, NY).Results
Patients were included from October 2007 until
December 2010 and followed up for a period of 20 weeks;
796 eligible patients were randomized (Supplementary
Figure 1). Final analyses included 405 patients from the
intervention group and 378 patients from the control group
(Supplementary Figure 1). Baseline characteristics of the
intervention and control groups did not show statistically
significant differences (Table 1 and Supplementary Table 2)
except for the biologics used as co-medication at the study
start (intervention group, 3.7%; control group, 7.4%; P ¼
.027). Steroid use, the main co-medication for patients with
IBD, was similar for both groups during follow-up evalua-
tion (Supplementary Table 3). Overall, the thiopurine dose
was similar for the intervention and control groups
(Supplementary Table 4). Fifty-five (13.6%) patients in the
Table 1.Characteristics of the Study Population
Total Intervention group Control group
Total 783 (100%) 405 (100%) 378 (100%)
Male, n 354 (45.2%) 186 (45.9%) 168 (44.4%)
Age, y (SD) 41.0 (15.8) 41.6 (15.9) 40.5 (15.8)
Weight, kg (SD) 74.3 (16.2)a 73.9 (16.3) 74.7 (16.2)
Age of disease onset, y (SD) 35.7 (15.1)a 36.3 (15.4) 35.0 (14.8)b
Disease duration until treatment start,
median (minimum–maximum), y
1.2 (0–49.7)a 1.3 (0–45.0) 1.1 (0–49.7)b
Medication, n
Azathioprine 503 (64.2%) 256 (63.2%) 247 (65.3%)
6-mercaptopurine 279 (35.6%) 148 (36.5%) 131 (34.7%)
None startedc 1 (0.1%) 1 (0.3%) 0 (0%)
Drug dose start, mg/kg
Azathioprinec 2.0 (0–3.1) 2.1 (0–2.7) 2.2 (0–3.1)
6-mercaptopurine 1.1 (0–2.2) 1.2 (0–2.2) 1.2 (0–2.0)
Drug dose 20 weeks, mg/kg
Azathioprine 2.1 (0.5–3.1)d 2.1 (0.5–2.7)e 2.2 (0.6–3.1)f
6-mercaptopurine 1.0 (0.3–1.5)g 1.1 (0.3–1.5)h 1.1 (0.4–1.5)h
Co-medication, n
Corticosteroids 640 (81.7%) 336 (83.0%) 304 (80.4%)
Mesalamine 388 (49.6%) 198 (48.9%) 190 (50.3%)
Biologicals 43 (5.5%) 15 (3.7%) 28 (7.4%)
TPMT genotype, n
*1/*1 705 (90.0%) 365 (90.1%) 340 (89.9%)
*1/*2 7 (0.9%) 4 (1.0%) 3 (0.8%)
*1/*3A 58 (7.4%) 31 (7.7%) 27 (7.1%)
*1/*3C 12 (1.5%) 4 (1.0%) 8 (2.1%)
*3A/*3A 1 (0.1%) 1 (0.2%) 0 (0%)
Baseline ESR 15 (1–109)i 14 (1–109)j 15 (1–102)k
CD patients 16 (1–109)l 16 (1–109)m 16 (1–102)n
UC patients 12.5 (1–95)o 14 (1–95)p 10 (2–85)q
Increased baseline ESR 270 (42.7%)i 141 (42.1%)j 129 (43.3%)k
CD patients 176 (46.1%)l 91 (44.4%)m 85 (48.0)n
UC patients 90 (37.2%)o 50 (39.1%)p 40 (35.1%)q
Baseline CRP 8 (0–284)r 8 (0.6–214)s 7 (0–284)t
CD patients 9 (0.6–284)u 8 (0.6–91)v 10 (0.6–284)w
UC patients 6 (0–214)x 7 (1–214)y 5 (0–180)z
Increased baseline CRP 277 (37.4%)aa 144 (37.4%)bb 133 (37.5%)cc
CD patients 194 (43.2%)dd 96 (40.9%)ee 98 (45.8%)ff
UC patients 78 (27.8%)gg 48 (32.7%)hh 30 (22.4%)ii
NOTE. Table data show means (SD), n (percentage), or medians (minimum–maximum) for disease duration.
an ¼ 781. bn ¼ 376. cPatient was homozygous for a TPMT variant and did not start thiopurine medication in agreement with
therapeutic recommendations, this patient was included in the azathioprine group for start dose because this was the
medication planned. Other patients who did not start medication also were included in the planned medication group.
dn ¼ 323. en ¼ 162. fn ¼ 161. gn ¼ 208. hn ¼ 104. in ¼ 633. jn ¼ 335. kn ¼ 298. ln ¼ 382. mn ¼ 205. nn ¼ 177. on ¼ 242.
pn ¼ 128. qn ¼ 114. rn ¼ 564. sn ¼ 294. tn ¼ 270. un ¼ 356. vn ¼ 185. wn ¼ 171. xn ¼ 199. yn ¼ 107. zn ¼ 92. aan ¼ 740.
bbn ¼ 385. ccn ¼ 355. ddn ¼ 449. een ¼ 235. ffn ¼ 214. ggn ¼ 281. hhn ¼ 147. iin ¼ 134.
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group did not start with the advised dose, all but 1 patient
started with a lower dose (Supplementary Figure 1 and
Supplementary Table 5). Two patients (1 each in the
intervention and control groups) started treatment before
the dose was provided and 12 patients (5 in the interven-
tion group and 7 in the control group) did not start treat-
ment at the planned time point. In addition, 1 patient in this
study was homozygous for a TPMT variant and did not start
treatment according to the dose advice of 0–10% of the
standard thiopurine dose. The azathioprine starting dose
was not different between the intervention and controlgroups, but a significant difference was observed in the 6-
mercaptopurine starting dose (Supplementary Table 4)
(P ¼ .045), this could be attributed to our intervention
because the dose difference was evident only in patients
with a genetic variant in TPMT (P < .004), patients without
a variant were started on similar 6-mercaptopurine doses as
patients in the control group (P ¼ .27). Thiopurine treat-
ment was discontinued at similar rates in the intervention
(n ¼ 170; 42.0%) and control (n ¼ 143; 37.8%) groups; 266
(65.7%) and 262 (69.3%) of the patients were using thio-
purines for up to 20 weeks in the intervention and control
groups, respectively (Supplementary Table 4).
Table 2.Overview of the Primary and Secondary Adverse Effects That Occurred in the Study Population
Total population Intervention group Control group
RR (95% CI)n (%) N total n (%) N total n (%) N total
Primary outcome
Hematologic ADR 58 (7.5) 783 30 (7.4) 405 30 (7.9) 378 0.93 (0.57–1.52)
Secondary outcomes based
on blood levels
Signs of hepatotoxicity 203 (26.6) 762 106 (26.7) 397 98 (25.9) 371 1.01 (0.80–1.28)
Signs of pancreatitis 187 (25.0) 749 106 (27.2) 389 84 (22.2) 365 1.18 (0.92–1.52)
Signs of anemia 474 (62.1) 763 246 (61.8) 398 231 (61.1) 371 0.99 (0.89–1.11)
Secondary outcomes reported
by clinicians
General 324 (41.4) 783 161 (39.8) 405 163 (43.1) 378 0.92 (0.78–1.09)
Dizziness 125 (16.0) 783 59 (14.6) 405 66 (17.5) 378 0.83 (0.60–1.15)
Shivers 67 (8.6) 783 35 (8.6) 405 32 (8.5) 378 1.02 (0.65–1.61)
Fever 104 (13.3) 783 57 (14.1) 405 47 (12.4) 378 1.13 (0.79–1.62)
General malaise 213 (27.2) 783 109 (26.9) 405 104 (27.5) 378 0.98 (0.78–1.23)
Gastrointestinal 559 (71.4) 783 290 (71.6) 405 269 (71.2) 378 1.01 (0.92–1.10)
Stomach ache 395 (50.4) 783 205 (50.6) 405 190 (50.3) 378 1.01 (0.88–1.16)
Diarrhea 235 (30.0) 783 123 (30.4) 405 112 (29.6) 378 1.03 (0.83–1.27)
Reduced appetite 160 (20.4) 783 82 (20.2) 405 78 (20.6) 378 0.98 (0.74–1.29)
Nausea 317 (40.5) 783 160 (39.5) 405 157 (41.5) 378 0.95 (0.80–1.13)
Vomiting 120 (15.3) 783 63 (15.6) 405 57 (15.1) 378 1.03 (0.74–1.43)
Infections 30 (3.8) 783 13 (3.2) 405 17 (4.5) 378 0.71 (0.35–1.45)
Hepatic 54 (6.9) 783 27 (6.7) 405 27 (7.1) 378 0.93 (0.56–1.56)
Cholestasis 16 (2.0) 783 8 (2.0) 405 8 (2.1) 378 0.93 (0.35–2.46)
Cholangitis 3 (0.4) 783 1 (0.2) 405 2 (0.5) 378 0.47 (0.04–5.13)
Hepatitis 41 (5.2) 783 21 (5.2) 405 20 (5.3) 378 0.98 (0.54–1.78)
Steatosis 3 (0.4) 783 0 (0) 405 3 (0.8) 378 0.13 (0.01–2.57)
Dermatologic 171 (21.8) 783 83 (20.5) 405 88 (23.3) 378 0.88 (0.68–1.15)
Hair loss 52 (6.6) 783 26 (6.4) 405 26 (6.9) 378 0.93 (0.55–1.58)
Warts 9 (1.1) 783 5 (1.2) 405 4 (1.1) 378 0.93 (0.32–4.31)
Skin rash 136 (17.4) 783 65 (16.0) 405 71 (18.8) 378 0.85 (0.63–1.16)
Myalgia 114 (14.6) 783 62 (15.3) 405 52 (13.8) 378 1.12 (0.79–1.57)
Arthralgia 132 (16.9) 783 70 (17.3) 405 62 (16.4) 378 1.05 (0.77–1.44)
NOTE. The following reference values were used for the side effects based on blood levels: hematologic ADR: leukocyte count
3.0*109/L and/or platelet count <100*109/L; signs of hepatotoxicity: at least 1 liver enzyme (alkaline phosphatase, alanine
aminotransferase, aspartate aminotransferase, and/or g-glutamate transpeptidase) more than 2 the upper limit reference
value; and signs of pancreatitis: amylase and/or lipase blood level higher than the reference value. Fourteen patients (7 in each
group) with signs of pancreatitis developed pancreatitis on the initially started thiopurine. Pancreatitis is defined as the
presence of 2 of 3 criteria for pancreatitis (amylase or lipase levels more than 3 the upper limit reference value, stomach ache,
or radiologic discrepancies). Signs of anemia were a hemoglobin level lower than the reference value.
Clinicians scored the patients for the presence of ADRs, and these were scored as present or absent on case report forms
during every hospital visit of the patients. A patient was included once, in case a specific ADR was reported more than one
time. In the overall groups (general, gastrointestinal, hepatic, and dermatologic side effects) presented in the table, patients
might be counted more than once if they had more than one ADR in the specific group.
CI, confidence interval; RR, relative risk.





ATADR frequencies in the first 20 weeks after thiopurine
initiation are summarized in Table 2. The main outcome
measure of our study, hematologic ADRs (leukocyte count
3.0*109/L or platelet count <100*109/L), was observed in
30 patients in the intervention and control groups. Overall,
no significant differences in ADR frequencies were observed
between both groups (Table 2). Two patients died. One
patient was a heterozygous TPMT*3A carrier allocated to
the intervention group, starting treatment according to dose
advice (1.2 mg/kg), in addition to using mesalamine and
prednisone. CRP was increased from 6 to 29 mg/L and the
leukocyte count decreased from 5.1*109/L to 3.6*109/L inthe 3 days before treatment initiation. Three days after
treatment initiation the leukocyte count had decreased to
2.9*109/L, and the patient died from leukopenia resulting
from Escherichia coli sepsis with pneumonia. The other pa-
tient (without a TPMT variant) started azathioprine in
addition to infliximab and corticosteroids. The leukocyte
count decreased to 2.5*109/L on day 16, and azathioprine
treatment was stopped. From that moment on the patient
used prednisone, methotrexate, and infliximab as immuno-
suppressive treatment. On day 27 the patient was hospi-
talized with Pneumocystis carinii pneumonia (leukocyte
count, 8.0*109/L) and died on day 48.
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ported frequencies (Table 1).15 One person (0.1%) was ho-
mozygous for TPMT*3A and 77 patients (9.8%) were
heterozygous carriers of a TPMT variant. Enzyme activity
measurements showed that patients carrying a genetic
variant had a lower TPMT enzyme activity than patients
without a variant (Supplementary Figure 2). Twelve patients
without one of the pretested variants had low TPMT enzyme
activity (<60 mg 6-methylguanine/mmol hemogloblin per
hour), one of the patients developed leukopenia. Complete
sequencing of the TPMT gene coding region showed a known
silent variant (rs2842934; Ile158Ile, TPMT*1S) in 4 of the 12
patients.19 Only 1 of these patients developed a hematologic
ADR.
Thirty patients in each group developed a hematologic
ADR, the majority, 29 in each group, developed leukopenia.
A reduced platelet count was observed in 3 patients (2
patients also developed leukopenia) in the intervention
group and in 2 patients (1 patient also developed leuko-
penia) in the control group. The intention-to-treat analysis
showed no difference in the occurrence of hematologic
ADRs between the intervention and control groups (7.4%
vs 7.9%; relative risk, 0.93; 95% confidence interval,
0.57–1.52) (Table 2). An analysis excluding patients on bi-
ologicals was performed because biological use differed
between the intervention and control groups at baseline.
This did not show any difference in hematologic ADRs be-
tween both groups (7.4% vs 6.7%). Limiting the analysis to
only those patients who actually started treatment showed
similar results (7.5% vs 8.1%). In addition, we did not
observe significant differences in the median time to a he-
matologic ADR (in those patients who developed an ADR)
between the intervention (42 days; interquartile range, 69
days) and control (56 days; interquartile range, 58 days)
groups, the number of patients who developed an ADR in
the first 8 weeks did not differ between groups (18 in each
group). Post hoc analysis of the subgroup of patients car-
rying a TPMT variant (*2, *3A, or *3C) , which included only
those patients who started treatment at the study start,
showed that a personalized dose regimen based on pre-
treatment genotyping resulted in a statistically significant





TPMT variant carriers 1 of 39 (2.6%)a
No TPMT variant 29 of 360 (8.1%)
NOTE. No deviations from Hardy–Weinberg equilibrium were obs
The patient homozygous TPMT*3A was randomized to the interv
heterozygous for TPMT*2 (n ¼ 4), TPMT*3A (n ¼ 30), or TPMT
control group, all patients were heterozygous, TPMT*2 (n ¼ 3),
CI, confidence interval; RR, relative risk.
aPatient died from leukopenia caused by E coli sepsis with pnerisk, 0.11; 95% confidence interval, 0.01–0.85) (Table 3). In
the intervention group only 1 of 39 patients carrying a
TPMT variant (2.6%) developed a hematologic ADR
compared with 8 of 35 patients in the control group
(22.9%). Analysis of the subset of patients with a genetic
variant who had not received biologicals (n ¼ 69) also
showed fewer instances of hematologic ADRs (P ¼ .011). No
difference in the occurrence of hematologic ADRs between
the intervention and control groups was found for the pa-
tients without a TPMT variant (P ¼ .47) (Table 3).
Several approaches were used to investigate whether a
thiopurine dose reduction in the TPMT variant carriers in the
intervention arm resulted in effective treatment. First, the
disease activitywas assessed.We did not observe statistically
significant differences in clinical outcome (disease activity)
between both groups at baseline in an intention-to-treat
analysis (P ¼ .13 for HBI; P ¼ .83 for partial Mayo) and 20
weeks after treatment initiation (P ¼ .18 for HBI; P ¼ .14 for
partial Mayo). A decrease in the median disease activity
scores after 20 weeks was observed in both treatment
groups, and in patients with and without the genetic variant
(Figure 1). Both groups also showed similar rates of clinical
remission (Supplementary Table 6). To assess treatment ef-
ficacy the change in ESR and CRP between treatment start
and 20 weeks was evaluated (Supplementary Table 6). This
showed a statistically significant difference for the absolute
ESR change in patients with a genetic variant (P ¼ .042,
for the benefit of patients in the intervention group).
Besides clinical outcome we also evaluated treatment
efficacy by measuring 6-thioguanine nucleotide and 6-
methylmercaptopurine ribonucleotide metabolite levels at
week 8. This was performed to investigate whether thio-
purine dose reduction in TPMT variant carriers in the inter-
vention arm resulted in effective treatment (Figure 2 and
Supplementary Figure 3). Comparison of patients with a
TPMT variant showed that a reduced thiopurine dose resul-
ted in 6-thioguanine nucleotide levels within the therapeutic
range, whereas a standard dose resulted in clearly increased
6-thioguanine nucleotides levels (Figure 2A). In addition, 6-
thioguanine nucleotides and 6-methylmercaptopurine ribo-
nucleotide concentrations in patients without a genetic
variant did not differ between the intervention and controlthe Intervention and Control Groups
Control RR (95% CI)
370
29 (7.8%)
8 of 35 (22.9%) 0.11 (0.01–0.85)
22 of 335 (6.6%) 1.2 (0.72–2.09)
erved (238G>C, P ¼ .9; 460G>A, P ¼ .93; 719A>G, P ¼ .67).
ention group, the other patients in the intervention group were
*3C (n ¼ 4). The following genotypes were observed in the
TPMT*3A (n ¼ 26), and TPMT*3C (n ¼ 6).
umonia 3 days after thiopurine treatment start.
Figure 1. Box-plots for disease activity scores for patients with (A) Crohn’s disease (HBI) and (B) ulcerative colitis (partial
Mayo). Disease activity scores are shown for the intervention (grey bars) and control (white bars) groups. The HBI can range
from 0 to 19 and the partial Mayo score can range from 0 to 9, a higher score means higher disease activity. The numbers
indicated for each set of boxes indicates the number of patients for the intervention and control groups, respectively. The
boxes indicate the 25th to 75th percentiles and the medians are indicated by a horizontal line in the box. Whiskers indicate the
1.5 interquartile range. Open circle indicates outliers (>1.5 interquartile range), and extreme outliers (>3 interquartile range) are
indicated by an asterisk. The x-axis indicates the number of patients analyzed.





ATgroups, indicating that both groups were equally adherent to
treatment. The highest 6-methylmercaptopurine ribonucle-
otides concentrations were, as expected, observed in patients
without a genetic TPMT variant (Figure 2B), followed by
patients with a variant on standard thiopurine dose (control
group); lowest levels were observed in patients treated with
a reduced thiopurine dose. Six patients (1 in the intervention
and 5 in the control group) had undetectable metabolite
levels at week 8 after thiopurine initiation, suggesting
noncompliance.
We also explored whether in addition to group allocation
other baseline factors (co-medication, sex, age, and weight)
were associated with the development of a hematologic
ADR. We observed more hematologic ADRs in patients using
biologics (P ¼ .002).Discussion
The TOPIC trial, a large randomized controlled trial
studying the effect of TPMT genotyping before thiopurine
treatment in IBD patients, showed no significant difference
in the risk of a hematologic ADR or treatment efficacy be-
tween the intervention and control groups. Post hoc analysis
indicated that TPMT screening significantly reduced the riskof a hematologic ADR in the subgroup of patients with a
genetic variant.
Forty percent of the patients discontinued thiopurine
treatment because of adverse effects, which is relatively
high compared with previous reports.6 Taking the patients
with a successful re-challenge into account, we observed
drop-out rates consistent with those in the literature.
Despite the high discontinuation rate, we did not observe
increased frequencies of hematologic ADRs in our popula-
tion.1 Thus, the TOPIC trial accurately reflects the general
IBD population treated with thiopurines.
We could not show a difference in the risk for occur-
rence of a hematologic ADR between the intervention and
control groups. Other ADRs commonly observed in patients
treated with thiopurines also showed comparable fre-
quencies in the 2 groups. This latter finding was in line with
expectations, because, for example, hepatotoxicity, malaise,
and pancreatitis do not seem to be linked to low TPMT
activity, as a meta-analysis of 1309 patients confirmed.20
The meta-analysis, however, showed a higher rate of bone
marrow toxicity and overall ADR development (ie, all ADRs
that required dose reduction).
A subgroup analysis in patients with a variant in the
TPMT gene showed that the intervention strongly reduced
Figure 2. Box-plots for steady-state metabolite levels of (A) 6-thioguanine nucleotides and (B) 6-methylmercaptopurine ri-
bonucleotides in pmol/8*108 red blood cells measured at 8 weeks of treatment. The therapeutic range of 6-thioguanine
nucleotide metabolites (235 and 490 pmol/8  108 red blood cells) and normal range levels of 6-methylmercaptopurine ri-
bonucleotides (<5700 pmol/8*108 red blood cells) are indicated with horizontal lines in panels A and B, respectively. The boxes
indicate the 25th to 75th percentiles, and the medians are indicated by a horizontal line in the box. Whiskers indicate the 1.5
interquartile range. Open circle indicates outliers (>1.5 interquartile range), and extreme outliers (>3 interquartile range) are
indicated by an asterisk. The number of patients analyzed are indicated on the x-axis. A statistically significant difference in
6-thioguanine nucleotides (P ¼ .004) and 6-methylmercaptopurine ribonucleotides (P < .001) was observed between the
intervention and control groups for patients carrying a TPMT variant. Similar metabolite levels were observed when excluding
patients who had a dose change before 8 weeks of thiopurine therapy (Supplementary Figure 3).
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AThematologic ADR frequency from 22.9% to 2.6%. Our data
confirmed the meta-analysis including 47 mainly retro-
spective studies, which showed an association between
decreased TPMT enzyme activity (based on genotype or
phenotype) and an increased risk for leukopenia.3 In
agreement with previous reports, the TOPIC trial also
showed that pretreatment TPMT genotyping cannot prevent
all cases of thiopurine-related hematologic ADRs, suggesting
that other factors play a role in the development of these
ADRs.21 The results also show that patient TPMT enzyme
activity measurements would not have identified the other
patients with leukopenia (1 patient of 11 with low enzyme
activity developed leukopenia). It is possible that patients
with leukopenia carry genetic variants in TPMT other than
those analyzed.15 However, sequencing of TPMT for 11 pa-
tients with the low TPMT enzyme activity who were nega-
tive for the 3 common TPMT variants did not show other
functional mutations, indicating that sequencing the com-
plete TPMT gene would not identify additional patients at
risk for leukopenia. Several studies have suggested that
genetic variants in other genes in thiopurine metabolism are
associated with thiopurine-induced leukopenia.14,22 A few
studies have shown that analyzing variants in 2 or more
genes involved in thiopurine metabolism, including
TPMT, may enhance the prediction of leukopenia,14,23–26 but
further large-scale studies are warranted. Besides geneticfactors, viral infections during thiopurine treatment may
induce the development of leukopenia.21 Finally, co-
medication might make patients more susceptible to
leukopenia.27 For this reason, we excluded patients
receiving allopurinol as a co-medication.28 However, other
commonly used treatments for IBD (eg, sulfasalazine and
mesalamine) also are implicated in the development of
leukopenia.29,30 And in this study, we have shown that
concurrent biologics’ use at treatment initiation is linked to
hematological ADR development. These nongenetic factors
should be taken into consideration before thiopurine initi-
ation because they might interfere with the genotype-guided
dosing. We observed a difference in biologics use at baseline
between the intervention and control groups. Therefore, we
also performed an analysis in patients who did not receive
biologics. In this group we also showed that pretreatment
genotyping resulted in a lower occurrence of hematologic
ADRs. We concluded that concurrent biologics use does not
interfere with the predictive ability of pretreatment TPMT
genotyping for hematologic ADRs.
Importantly, similar treatment efficacy based on disease
activity scores was observed in the intervention and control
groups, which indicates that a reduced thiopurine dose does
not result in undertreatment. The same was evident at
the active metabolite level, in which patients receiving a
genotype-guided thiopurine dose-reduction had a median





ATsteady-state 6-thioguanine nucleotide level within the
therapeutic range.31–33
The results of the TOPIC study indicated that 200 pa-
tients would need to be genotyped to avoid 1 episode of a
hematologic ADR (7.4% vs 7.9%; ie, 0.5% risk difference).
The number needed to treat to avoid one episode of a
hematologic ADR would be 5 for at-risk individuals (risk
difference in patients with a genetic variant is 20.3; 2.6%
vs 22.9%). The huge difference between the number
needed to genotype and the number needed to treat can be
attributed to the low frequency of the screened genetic
variants in TPMT (w10%). This nicely illustrates the dif-
ficulty in trying to use whole-population randomized
studies to investigate the effectiveness of pharmacogenetic
testing: the high-risk genotype constitutes a small pro-
portion of the population (here 10%), which makes it
extremely hard to show a benefit for all patients; only a
portion of the population benefits. Post hoc power analysis
indeed showed that the subgroup analysis was powered
sufficiently (80% power with 38 patients showing hema-
tologic ADRs), but that a randomized controlled trial with
42,556 participants would be needed to show a benefit for
the entire intervention group (power of 80%, based on the
incidence of hematologic ADRs observed in our study
population).
A limitation of our study was that 12.5% of the patients
were not treated according to the advised dose. However,
this probably reflected the situation of genotype-guided
dosing in the clinical setting. In addition, the study was
performed in a nonblinded fashion. Gastroenterologists
might have been able to identify patients in the interven-
tion group receiving a reduced thiopurine dose advice (n ¼
40). However, it is not expected that these patients were
treated differently; all patients were monitored regularly
and because the study focused on the occurrence of (he-
matologic) ADRs, it was expected that gastroenterologists
would be more alert to ADR development in both the
intervention and control groups. Finally, the result of our
post hoc analysis should be considered with caution
because it was not corrected for multiple comparisons.
Thus, in general, large-scale randomized controlled trials
should focus their efforts specifically on the group that can
be expected to benefit from genotype-guided treatment, in
this specific case those patients with a TPMT variant.
Strong points of our study are its prospective design and
the fact that patients were included in general as well as
academic hospitals, and that the decision to start thio-
purine treatment was at the discretion of the gastroen-
terologist. This reflects the normal situation in which
patients with IBD are treated.
Current guidelines for thiopurine treatment mandate
regular hematologic monitoring to detect (severe) leuko-
penia. However, this is not a complete safeguard because
leukopenia can develop suddenly. It has been suggested that
pretreatment genotyping is relevant mainly for patients who
are homozygous carriers of a genetic variant in TPMT.9 We
show that pretreatment TPMT genotyping also is relevant
for patients heterozygous for a variant in TPMT. Impor-
tantly, a recent cost-effectiveness analysis (n ¼ 333), inwhich also no differences in the ADR rate between the
intervention and control groups was observed, indicated
that pretreatment TPMT genotyping had a probability of
71% to be cost effective, owing to lower resource use in the
intervention group.34 However, they observed a small
negative effect on the quality of life. This latter was not
evident from our results because treatment efficacy, as a
surrogate for quality of life, was similar between groups.
Pretreatment genotyping should not replace current hema-
tologic safety monitoring, but should be considered as a
(cost-effective) addition to optimize thiopurine treatment.
The results of the TOPIC trial showed no overall effect of
pretreatment TPMT screening followed by personalized
dosing on hematologic ADRs. However, the study, in com-
bination with the literature, shows that pretreatment TPMT
screening followed by personalized dosing reduces the risk
of leukopenia in patients carrying a genetic variant in TPMT
and indicates that pharmacogenetic TPMT testing should be
used as standard care to individualize thiopurine treatment
of IBD patients.
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Supplementary
Figure 1. Study design of
the TOPIC trial. AZA,
azathioprine; 6-MP, 6-
mercaptopurine.
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Supplementary Figure 2. TPMT enzyme activity distribution
in the study population. Overview of the enzyme activity (mg/
mmol hemoglobin per hour) distribution in patients (A) without
a genetic variant (n ¼ 705) and (B) with a genetic variant (n ¼
78) in the TPMT gene. Each bar represents 5 units of the scale
(eg, 0–5, >5–10). Patients not carrying a TPMT variant had a
mean enzyme activity for 6-methylguanine of 94.5 ± 19.0 mg/
mmol hemoglobin per hour, and in heterozygous patients the
mean TPMT enzyme activity of 6-methylguanine was 49.4 ±
10.7 mg/mmol hemoglobin per hour. The patient homozy-
gous for TPMT*3A had an enzyme activity of 0.50 mg 6-
methylguanine/mmol hemoglobin per hour before thiopurine
therapy.
Supplementary Figure 3. Box-plots for steady-state
metabolite levels 6-thioguanine nucleotides (6-TGN) and
6-methylmercaptopurine ribonucleotides (6-MMPR) after
exclusion of patients who received a dose change before 8
weeks of treatment start. Box-plots for steady-state metab-
olite levels of (A) 6-TGN and (B) 6-MMPR in pmol/8*108 red
blood cells after exclusion of patients who received a dose
change before 8 weeks of treatment start. Metabolite levels
were measured at 8 weeks of treatment. The therapeutic
range of 6-TGN metabolites (235 and 490 pmol/8  108 red
blood cells) and normal range levels of 6-MMPR (<5700
pmol/8*108 red blood cells) are indicated with horizontal lines
in panels A and B, respectively. The boxes indicate the 25th
to 75th percentile and the medians are indicated by a hori-
zontal line in the box. Whiskers indicate 1.5 interquartile
range. Open circle indicates outliers (>1.5 interquartile range)
and extreme outliers (>3 interquartile range) are indicated by
an asterisk. The numbers on the x-axis indicate the number of
patients analyzed.
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Supplementary Table 1.Overview of the Primers Used for Sequencing of the Protein-Coding Part of the TPMT Gene









NOTE. Polymerase chain reaction was performed on 10 ng DNA using AmpliTaq Gold 360 mastermix (Life Technologies). The
annealing temperature was 56C for all exons. Sequencing was performed using Sanger technology.
Supplementary Table 2.Overview of Baseline IBD Classification in the Study Population
Diseasea
Total population Intervention group Control group
CD UC CD UC CD UC
Total, n (%) 476 (61.0%) 300 (38.5%) 245 (60.5%) 157 (38.8%) 231 (61.1%) 143 (37.8%)
Presence of fistula 43 (9.3%)b 19 (7.8%)c 24 (10.5%)d
Localization CD known n ¼ 466 n ¼ 239 n ¼ 227
Ileum (L1) 159 (34.1%) 88 (36.3%) 71 (31.3%)
Colon (L2) 113 (24.2%) 52 (21.8%) 61 (26.9%)
Ileum and colon (L3) 194 (41.6%) 99 (41.4%) 95 (41.9%)
Localization UC known n ¼ 293 n ¼ 152 n ¼ 141
Proctitis ulcerosa (E1) 38 (13.0%) 23 (15.1%) 15 (10.6%)
Left-sided colitis (E2) 121 (41.3%) 67 (44.1%) 54 (14.3%)
Pancolitis (E3) 134 (45.7%) 62 (40.8%) 72 (19.0%)
NOTE. L indicates localization of Crohn’s disease and E indicates extent of ulcerative colitis, both according to the Montreal
classification.
aSeven patients in our study population (3 in the intervention group and 4 in the control group) had unclassified inflammatory
bowel disease.The total number of patients for whom fistulas were assessed: bn ¼ 468, cn ¼ 243, and dn ¼ 225.
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Supplementary Table 3.Corticosteroid Use in the Intervention and Control Groups
Intervention group (N ¼ 405) Control group (N ¼ 378)
Steroid use at t ¼ 0, n (%)
All steroids, systemic and local 328 (81.0) 306 (81.0)
Systemic steroids 321 (79.3) 293 (77.5)
Steroids initiated, n (%)
All steroids, systemic and local 74 (18.3) 67 (17.7)
Systemic steroids 56 (13.8) 57 (15.1)
Steroids discontinued, n (%)
All steroids, systemic and local 171 (42.2) 170 (45.0)
Systemic steroids 160 (39.5) 156 (41.3)
Steroids used during the follow-up period, n (%)
All steroids, systemic and local 348 (85.9) 322 (85.2)
Systemic steroids 340 (84.0) 309 (81.7)
Duration of steroid use,a mean (SD)
All steroids, systemic and local 0.71 (0.39) 0.71 (0.39)
Systemic steroids 0.66 (0.40) 0.66 (0.40)
aDuration was calculated as the percentage of the study period. Comparisons in steroid use between the intervention and
control groups, using the X2 test or the Mann–Whitney U test for the duration of steroid use, showed no statistically significant
differences.
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Azathioprine 2.0 (0–3.1) 506 2.1 (0–2.7) 258 1.1 (0–1.4) 27 2.2 (0–2.7) 231 2.2 (0–3.1) 248 2.1 (0–2.4) 22 2.2 (0–3.1) 226
6-Mercaptopurine 1.1 (0–2.2) 277 1.2 (0–2.2) 147 0.6 (0.5–0.8) 13 1.2 (0–2.2) 134 1.2 (0–2.0) 130 1.2 (0–1.5) 14 1.2 (0.6–2.0) 116
Dose week 20, mg/kg,
mean (minimum–maximum)
Azathioprine 2.1 (0.5–3.1) 323 2.1 (0.5–2.7) 162 1.0 (0.5–1.5) 15 2.1 (0.5–2.7) 147 2.2 (0.6–3.1) 161 2.1 (0.7–2.4) 18 2.2 (0.6–3.1) 143
6-Mercaptopurine 1.0 (0.3–1.5) 208 1.1 (0.3–1.5) 104 0.6 (0.3–1.0) 9 1.1 (0.4–1.5) 95 1.1 (0.4–1.5) 104 1.1 (0.8–1.3) 8 1.1 (0.4–1.5) 96
Treatment stop, n (%) 313 (40.0) 783 170 (42.0) 405 19 (47.5) 40 151 (41.4) 365 143 (37.8) 378 9 (25) 36 134 (39.2) 342
Treatment restart, n (%) 117 (14.9) 783 57 (14.1) 405 4 (10.0) 40 53 (14.5) 365 60 (15.9) 378 1 (2.8) 36 59 (17.3) 342
Dose change, n (%) 235 (30.0) 783 118 (29.1) 405 6 (15.0) 40 112 (30.7) 365 117 (31.0) 378 7 (19.4) 36 110 (32.2) 342
Thiopurine treatment
week 20, n (%)
531 (67.8) 783 266 (65.7) 405 24 (60) 40 242 (66.3) 365 262 (69.3) 378 26 (72.2) 36 239 (70.0) 342
Days thiopurine use,
mean (SD)b
0.59 (0.41) 783 0.59 (0.41) 405 0.57 (0.43) 40 0.59 (0.41) 365 0.59 (0.41) 378 0.62 (0.41) 36 0.59 (0.41) 342
aPatients not starting treatment were included in the azathioprine or 6-mercaptopurine group depending on the treatment that should be initiated.
bDays of thiopurine use were calculated as a percentage of the study period. Treatment stop describes the patients who discontinued treatment during the follow-up
period, this includes patients who subsequently restarted treatment. Comparisons between the intervention and control groups, using the X2 test or the Mann–
Whitney U test for dose and days of thiopurine use, showed statistically significant differences for 6-mercaptopurine dose at treatment initiation between the intervention
and control groups (P ¼ .045) and for azathioprine dose at week 20 (P ¼ .014). Azathioprine and 6-mercaptopurine doses were both significantly different between the







Supplementary Table 5.Patient Enrollment per Center and Number of Patients Starting With a Dose Not According to the
Provided Advice
Center number Total number of patients included Patients carrying a variant in TPMTa Protocol violationsa
1 48 (6.1) 5 (10.4) 6 (12.5)
2 10 (1.3) 0 (0) 1 (10)
3 34 (4.3) 4 (11.8) 4 (11.8)
4 14 (1.8) 1 (7.1) 1 (7.1)
5 33 (4.2) 6 (18.2) 8 (24.2)
6 20 (2.6) 1 (5) 1 (1.4)
7 38 (4.9) 4 (10.5) 8 (4.75)
8 19 (2.4) 2 (10.5) 3 (15.8)
9 54 (6.9) 5 (9.3) 17 (31.5)
10 5 (0.6) 1 (20) 1 (20)
11 28 (3.6) 0 (0) 0 (0)
12 59 (7.5) 7 (11.9) 8 (13.6)
13 84 (10.7) 9 (10.7) 7 (8.3)
14 31 (4.0) 5 (16.1) 4 (12.9)
15 51 (6.5) 8 (15.7) 18 (35.3)
16 10 (1.3) 1 (10) 0 (0)
17 26 (3.3) 2 (7.7) 1 (3.8)
18 29 (3.7) 3 (10.3) 3 (10.3)
19 48 (6.1) 2 (4.2) 2 (4.2)
20 2 (0.3) 0 (0) 0 (0)
21 40 (5.1) 2 (5.0) 2 (5.0)
22 19 (2.4) 2 (10.5) 1 (5.3)
23 47 (6.0) 4 (8.5) 5 (10.6)
24 1 (0.1) 0 (0) 0 (0)
25 4 (0.5) 0 (0) 2 (50)
26 1 (0.1) 1 (100) 0 (0)
27 18 (2.3) 2 (11.1) 6 (33.3)
28 4 (0.5) 0 (0) 1 (25)
29 3 (0.4) 0 (0) 0 (0)
30 3 (0.4) 1 (33.3) 0 (0)
Total 783 (100) 78 (10.0) 110 (14.0)
NOTE. Data shown are n (%).
aPercentage of the number of patients included at a particular center.
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Remissiona 55 (69.6%) 79 9 (75.0%) 12 46 (68.7%) 67 58 (67.4%) 86 9 (90.0%) 10 49 (64.5%) 76
HBI 19 (61.3%) 31 1 (50.0%) 2 18 (62.1%) 29 31 (75.6%) 41 4 (80.0%) 5 27 (75.0%) 36
Partial Mayo 36 (75.0%) 48 8 (80.0%) 10 28 (73.7%) 38 27 (60.0%) 45 5 (100.0%) 5 22 (55.0%) 40
ESRb all patients
Absolute change 2.0 (-83.0 to 90.0) 208 8.0 (-12.0 to 74.0)c 19 2.0 (-83.0 to 90.0) 189 1.0 (-45.0 to 88.0) 190 0.0 (-18 to 19)c 17 1.0 (-45.0 to 88.0) 173




41 (45.1%) 91 9 (64.3%) 14 32 (42.1%) 76 41 (47.1%) 87 3 (37.5%) 8 38 (50.0%) 76
ESRb CD patients
Absolute change 2.0 (-36.0 to 90.0) 122 1.0 (-8.0 to 60.0) 8 2.0 (-36.0 to 90.0) 114 1.0 (-42.0 to 88.0) 114 0.0 (-18.0 to 14.0) 11 1.0 (-42.0 to 88.0) 103




23 (43.4%) 53 3 (75.0%) 4 20 (41.7%) 48 25 (46.3%) 54 1 (20.0%) 5 24 (49.0%) 49
ESRb UC patients
Absolute change 2.5 (-83.0 to 74.0) 86 21.0 (-12.0 to 74.0) 11 2.0 (-83.0 to 58.0) 75 0.0 (-45.0 to 65.0) 71 0.0 (-6.0 to 19.0) 6 0.0 (-45.0 to 65.0) 65




18 (47.4%) 38 6 (60.0%) 10 12 (42.9%) 28 13 (46.4%) 28 2 (66.6%) 3 11 (45.8%) 24
CRPb all patients
Absolute change 1.4 (-264.0 to 209.0) 182 1.0 (-57.0 to 209.0) 19 1.7 (-264.0 to 85.0) 163 1.0 (-108.0 to 178.0) 176 2.5 (-42.0 to 29.1) 14 1.0 (-108.0 to 178.0) 162




60 (51.7%) 116 7 (50%) 14 53 (52.0%) 102 65 (55.1%) 113 4 (44.4%) 9 61 (58.7%) 104
CRPb CD patients
Absolute change 2.0 (-223.0 to 85.0) 122 -1.0 (-57.0 to 45.0) 11 2.0 (-223.0 to 85.0) 111 1.0 (-108.0 to 67.0) 113 3.0 (-42.0 to 29.1) 10 1.0 (-108.0 to 67.0) 103




38 (48.7%) 78 2 (33.3%) 6 36 (50.0%) 72 41 (50.6%) 81 3 (42.9%) 7 38 (51.4%) 74
CRPb UC patients
Absolute change 1.0 (-264.0 to 209.0) 59 22.0 (-17.0 to 209.0) 8 0.7 (-264.0 to 84.0) 51 0.5 (-49.0 to 178.0) 58 2.3 (-7.0 to 3.0) 4 0.0 (-49.0 to 178.0) 54




22 (57.9%) 38 5 (62.5%) 8 17 (56.7%) 30 22 (78.6%) 28 1 (50.0%) 2 21 (80.8%) 26
NOTE. Values are given as either n (%) or medians (minimum–maximum).
aNumber (%) of patients that achieved clinical remission at week 20 who were not in remission at treatment initiation. Remission is defined as HBI score less than 5 and
partial Mayo score less than 3.
bAbsolute and percentage change for ESR and CRP is shown as a median and range. Absolute change is calculated as a baseline value minus the value at 20 weeks, thus
negative values indicate an increase from baseline to 20 weeks. The percentage change is calculated as follows: ([baseline value - value at 20 weeks]/baseline value)*100%.
cThe absolute change in ESR was statistically significant between the patients with a genetic variant (P¼ .042), with patients in the intervention group showing better results.
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